Acasti Pharma Inc. Reports Positive Test Results (NEPT)
Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. (Nasdaq: NEPT) reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre™ on C-reactive protein levels, a biomarker of CardioVascular Disease risk and associated with diabetes and obesity.
Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.